MicroRNAs are short single-stranded RNAs derived from precursors through processing by RNase III enzymes Drosha and Dicer. They function as gene regulators in a variety of physiological processes. Abnormal expression of microRNA is highly implicated in oncogenesis and can be caused by aberrations in levels of transcription of primary microRNA precursors, as well as post-transcriptional alterations. 1 MiR-155 is one of the most well-known oncogenic microRNA. 2 MiR-155 overexpression has been documented in a number of lymphoid neoplasms, such as chronic lymphocytic leukemia, diffuse large B-cell lymphomas, Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. [3] [4] [5] However, BIC (the precursor for miR-155) and miR-155 were not detected or detected at very low levels in adult primary Burkitt lymphoma (BL) tissues. 6 A defect in BIC processing has been postulated in BL cells. 7 In this study, we evaluated the capacity of BIC to be processed into mature miR-155 by transient transfection of BL cell line Ramos and expression analysis of BIC and miR-155 in primary BL cases.
EBV(-) BL cell line Ramos and human embryonic kidney 293 cells were transiently transfected with pcDNA3 empty vector, pcDNA3.BIC.ex3 or pcDNA.BIC.fl. The construction of pcDNA3.BIC.ex3 has been described previously. It carries the short form of BIC exon 3, where pre-miR-155 resides. 3 pcDNA.BIC.fl was obtained by subcloning the full-length BIC cDNA (RZPD, Berlin, Germany) in pcDNA3. 7 Ramos cells transfected with empty vector harbors only a low level of miR-155, approximately 10% that of the prototypic activated B-cell type-DLBCL cell line OCI-Ly3, which harbors high levels of BIC and miR-155. 3 Transient transfection with the miR-155 expression plasmids in Ramos cells resulted in 420-fold increase in miR-155 ( Figure 1a) . Similarly, transient transfection of 293 cells increased miR-155 levels in these cells by 430-fold. We also looked at the levels of BIC in these transfectants by quantitative real-time PCR using primers and probe specific to exon 3 on cDNA reverse-transcribed from total RNA that is free of genomic Figure 1 MiR-155 is processed efficiently from BIC in BL cells. Ramos or 293 cells were transfected with pcDNA3 (vector) or pcDNA3-based miR-155 expression plasmid carrying BIC exon 3 (BIC ex 3) or full-length BIC (BIC fl). MiR-155 (a) and BIC (b) levels were determined 24 h posttransfection. MiR-155 was measured by real-time PCR using the Taqman MicroRNA miR-155 assay set (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's recommended protocol. For quantitative BIC transcript analysis, genomic DNA was removed from total RNA by Turbo DNase (Stratagene, La Jolla, CA, USA). Total RNA (1 mg) was used for reverse transcription, and about 50 ng of cDNA was subjected to realtime PCR analysis with the following primers: forward primer, 5 0 -GGTTTTTGCCTCCAACTGAC-3 0 ; reverse primer, 5 0 -TTATCCAGCAGGGT GACTCAT-3 0 , using SYBR Green PCR Master Mix (Applied Biosystems) and AmpliTaqGold DNA Polymerase (Applied Biosystems) in conditions recommended by manufacturer. 5S RNA and b-glucuronidase were used as normalization for miR-155 and BIC, respectively. Both miR-155 and BIC measurements were performed in duplicates. Amounts of miR-155 and BIC were calculated by the standard curve method and expressed relative to OCI-Ly3 ( ¼ 100). The values shown represent the average (±s.e.) of three independent transfection experiments. MiR-155 and BIC levels are significantly higher in cells transfected with BIC expression plasmids ( Letters to the Editor DNA. Ramos cells transfected with miR-155 expression plasmids had about four-to eightfold higher levels of BIC compared to the controls, while BIC levels in 293 cells transfected with the same miR-155 expression plasmids are about 60-to 80-fold higher (Figure 1b) . We utilized the miR-155:BIC as an estimation of the efficiency of processing of BIC into mature miR-155. 3 Based on this ratio, the processing efficiency of endogenous BIC in Ramos cells is about 16 times that in OCI-Ly3. The processing efficiency of exogenous BIC in these cells is even higher compared to endogenous BIC (Pp0.01), and also higher than in 293 cells regardless whether exogenous BIC is expressed from BIC exon 3 or full-length BIC (Po0.05) (Figure 1c) . Based on the above results, we can conclude that there are no intrinsic defects in BIC/miR-155 processing in BL cells.
To further confirm the absence of an intrinsic blockade in BIC/miR-155 processing in BL cells, we also analyzed six primary BL cases for miR-155 and BIC expression. These BL cases harbor much lower levels of BIC only about 1-3% compared to OCI-Ly3 (Figure 2a) . However, in contrast to previous results based on Northern analysis, 7 miR-155 was clearly detectable, albeit at relatively low levels, in these cases using the more sensitive RT-PCR method (Figure 2b ). The levels of BIC and miR-155 found in these primary BL cases are similar to those detected in the Ramos cell line. Importantly, similar to Ramos cells, the miR-155:BIC ratios in primary BL cases are much higher (7.9 times on average) relative to OCILy3 (Figure 2c ). Moreover, they are similar to the ratios previously determined for Hodgkin's lymphoma cell lines. 3 Our results provide evidence that the low levels of miR-155 in both cultured and primary BL cells are determined mainly by low levels of BIC transcription rather than a deficiency in BIC/ miR-155 processing.
In the study by Kluiver et al., 7 evidence for a blockade in BIC/ miR-155 processing in BL was provided by the isolation of stable transfectants of Ramos cells that harbor high levels of enforced BIC but lack miR-155. It is conceivable that the absence of miR-155 in these stable transfectants is a result of clonal selection. A high level of miR-155 in BL cells is possibly unfavorable for cell proliferation and/or survival, and thus only cells spontaneously acquiring mechanisms to shut off miR-155 in the presence of enforced BIC expression, for example by downregulating BIC/ miR-155 processing, have the growth advantage and thus selected clonally. This selection will not be operating in transient transfectants. It will be interesting to test this hypothesis by analyzing global gene expression patterns in Ramo cells with transiently overexpressed miR-155 to determine if genes detrimental to cell survival and/or growth are induced by miR-155 expression. Although our results indicate no intrinsic defects in BIC/miR-155 processing in BL cells, they may harbor a normally quiescent BIC/miR-155 blockade mechanism that is activated upon B-cell receptor triggering in BL cells, as suggested by the inability to generate miR-155 despite BIC induction upon B-cell receptor activation. 7 However, a very recent study demonstrated both BIC and miR-155 induction upon B-cell receptor engagement. 8 This discrepancy may be attributed to the difference in concentrations of anti-IgM used in the stimulation experiments between the two studies. The concentration of anti-IgM used in the latter study was 4300-fold higher than the other study. This difference in ligand concentrations may produce subtle differences in signaling downstream of B-cell receptor, which may affect the status of BIC/miR-155 processing. The potential mechanism of activation-induced blockade of BIC/miR-155 processing in BL cells and how it may contribute to BL pathogenesis need to be elucidated.
Our results also offer clues to the identification of some of the determinants that may influence BIC processing. The miR-155:BIC ratio is higher in Ramos cells transfected with the full-length BIC sequence than those transfected with only the BIC exon 3 sequence (Figure 1c ; Po0.05). A similar trend was observed in 293 cells (P ¼ 0.06). These results suggest that RNA sequence and/or structure beyond pre-miR-155, for example those present in exon 1 or 2, influence BIC/miR-155 processing. Further experiments are necessary to better define the determinants within BIC that can affect its processing.
Understanding the signaling events and RNA sequence and/or structural determinants that can regulate BIC/miR-155 processing will facilitate development of novel strategy to modify miR-155 levels in hematopoietic malignancies. The diagnosis of severe congenital neutropenia (SCN) is clinically based on profound persistent neutropenia (absolute neutrophil count (ANC). We previously reported on an SCN patient who transformed to CALLA þ B-cell acute lymphoblastic leukemia (ALL). No constitutive mutation in the ELA2 gene or acquired mutation in the G-CSFR gene could be detected. 1 The female patient was the first-born child of parents who were second-degree relatives and she was diagnosed at the age of 5 months. There was no family history for an increased susceptibility to infection. The patient had a history of early onset of potentially life-threatening bacterial infection. Her white blood cell count was 6.3 Â 109 l À1 and differential count was 1% neutrophils (ANC: 0.063 Â 109 l À1 ), 30% monocytes, 63% lymphocytes and 6% eosinophils. Her bone marrow aspiration smear revealed apparent maturation arrest at promyelocyte stage. At 7 months of age, before initiation of granulocyte-colony stimulating factor (G-CSF) treatment, her peripheral blood revealed 20% lymphoblasts. Immunological and viral markers were normal and negative, respectively. Bone marrow and flow cytometric examination revealed 40-50% lymphoblasts, consistent with CALLA þ B-cell ALL (pre-B). The patient attained remission following induction therapy (St Jude Total XI study ALL protocol). She responded to G-CSF treatment but died due to septicemia during maintenance chemotherapy.
We hypothesized that HAX-1 gene mutation could be the cause of congenital neutropenia in this case and detect the mutation p.Q123fsX4 homozygously. Heterozygosity of the parents could be shown confirming SCN with autosomal recessive inheritance. This is the first report on a patient with secondary overt leukemia in SCN caused by HAX-1 gene mutation, indicating that a risk of malignant transformation is also associated with HAX-1 gene mutation.
Patients with SCN may transform to myelodysplastic syndrome (MDS) and acute myeloblastic leukemia. Most of these patients were treated with G-CSF. 2 In our patient, ALL developed without G-CSF treatment and no acquired G-CSFR mutation known to be associated with leukemogenesis in nearly 80% of SCN/leukemia was detectable. In light of the related literature and according to the rapid progression shown by our patient, the cause leading to malignant transformation in SCN is not yet clearly known. G-CSFR mutations were determined in three patients with HAX1 mutation, and one of them transformed to MDS. 3 There are also reports of two other SCN patients with G-CSFR mutation who transformed to ALL. 4, 5 We could show that SCN caused by HAX1 mutation can evolve to acute leukemia. Further studies will be necessary to determine the prevalence of malignant transformation and the mechanisms of leukemogenesis in this patient group.
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